Akanda Corp. faces Nasdaq delisting risk for late 20-F; cancels repeatedly adjourned shareholder meeting
AKAN has more than doubled off its 52-week low of $2.295.
Summary
Akanda Corp. is at risk of Nasdaq delisting due to a late annual report filing and has cancelled a key shareholder meeting after multiple adjournments, signaling severe governance and operational challenges.
Key Events · Corporate Governance and Compliance · AKAN
-
Nasdaq Non-Compliance Notice
Akanda Corp. received a letter from Nasdaq for failing to file its Annual Report on Form 20-F for the fiscal year ended December 31, 2025, by the required due date, violating Nasdaq Listing Rule 5250(c)(1).
-
Delisting Risk
The company must submit a plan to regain compliance by July 19, 2026. If Nasdaq accepts the plan, an extension may be granted until November 16, 2026. Failure to regain compliance could lead to delisting.
-
Shareholder Meeting Cancelled
The special shareholder meeting, originally scheduled for March 31, 2026, and repeatedly adjourned, was cancelled due to a persistent lack of quorum. This prevents a vote on critical capital structure changes.
Analysis · AKAN · Life Sciences
Akanda Corp. received a Nasdaq non-compliance notice for failing to file its annual 20-F report, putting its listing at risk. This is compounded by the cancellation of a critical shareholder meeting, which had been repeatedly postponed due to a lack of quorum, highlighting significant governance challenges and an inability to secure shareholder participation for important capital structure decisions.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 45.6% of the 296 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.48%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AKAN was trading at $26.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.5M. The 52-week trading range was $2.30 to $209.03. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.